Rockwell Medical, Inc. (NASDAQ:RMTI) tinted gains of +2.71% (+0.14 points) to US$5.31. The volume of 0.14 Million shares climbed down over an trading activity of 241.88 Million shares. EPS ratio determined by looking at last 12 month figures is -0.54. Over the same time span, the stock marked US$8.7 as its best level and the lowest price reached was US$4.84. The corporation has a market cap of US$282.33 Million.
Rockwell Medical, Inc. (NASDAQ:RMTI)’s earnings per share has been growing at a 28.1 percent rate over the past 5 year when average revenue increase was noted as 2.8 percent. The return on equity ratio or ROE stands at -76.5 percent while most common profitability ratio return on investment (ROI) was -78.8 percent. The company’s institutional ownership is monitored at 32.1 percent. The company’s net profit margin has achieved the current level of -48.1 percent and possesses 2.4 percent gross margin.
Daily Analyst Recommendations
A number of key analysts, polled by FactSet, shared their views about the current stock momentum. The forecast of 1 surveyed investment analysts covering the stock advises investors to Buy stake in the company. At present, 0 analysts call it Sell, while 0 think it is Hold. Recently, analysts have updated the overall rating to 1. 0 analysts recommended Overweight these shares while 0 recommended Underweight, according to FactSet data.
Israel Chemicals Ltd. (NYSE:ICL) is worth US$6.3 Billion and has recently risen 2.7% to US$4.94. The latest exchange of 0.24 Million shares is below its average trading activity of 225.28 Million shares. The day began at US$4.9 but the price moved to US$4.9 at one point during the trading and finally capitulating to a session high of US$4.98. The stock tapped a 52-week high of US$4.95 while the mean 12-month price target for the shares is US$4.5.
Currently, the stock carries a price to earnings ratio of 17.33, a price to book ratio of 2.21, and a price to sales ratio of 1.16. For the past 5 years, the company’s revenue has grown 0%, while the company’s earnings per share has grown -17.7%. With an institutional ownership near 0%, it carries an earnings per share ratio of 0.29.
Inside Look At Analysts Reviews
Latest analyst recommendations could offer little help to investors. The stock is a Buy among 1 brokerage firms polled by Factset Research. At present, 2 analysts recommended Holding these shares while 0 recommended sell, according to FactSet data. 0 analysts call it Underweight, while 0 think it is Overweight. Recently, investment analysts covering the stock have updated the mean rating to 2.33.